Transscleral Iontophoresis of Dexamethasone

Tim T. Lam, Deepak P. Edward, Xiu An Zhu, Mark O M Tso

Research output: Contribution to journalArticle

Abstract

Transscleral iontophoresis has been suggested to be a potentially useful noninvasive technique in intravitreal introduction of ionizable drugs, such as cefazolin sodium, ticarcillin disodium, and gentamicin sulfate. To investigate the usefulness of this technique in the administration of corticosteroids, we performed transscleral iontophoresis of dexamethasone sodium phosphate (300 mg/mL, 20 mmol/L edetic acid [EDTA]) into rabbits at a current of 1.6 mA for 25 minutes. Eyes were enucleated at different time intervals and frozen in liquid nitrogen. The frozen vitreous bodies and adherent sensory retina were collected and sonicated, and dexamethasone levels were measured using high-pressure liquid chromatography. In addition, to study the facilitation of drug transport by cryotherapy, a second group of rabbits were given a single application of cryotherapy (—78°C, 45 seconds) 3, 7, and 14 days before iontophoresis in the same region. Without cryotherapy, the initial level of dexamethasone in the vitreous body—sensory retina after iontophoresis was 139.3 ± 51.5 mg/L (mean ± SE) (n = 6) with a half-life of less than 2 hours. In the cryotreated group, the levels of dexamethasone immediately after iontophoresis 3, 7, and 14 days after cryotherapy were 61.5 ± 31.7 (n = 6), 88.4 ± 55.1 (n = 6), and 112.2 ± 32.5 (n = 6) mg/L, respectively, indicating that levels were lower compared with the group without cryotherapy. Our results suggest that a high dose of dexamethasone can be delivered by using this noninvasive technique and that cryotherapy before iontophoresis does not increase drug levels in the vitreous body.

Original languageEnglish (US)
Pages (from-to)1368-1371
Number of pages4
JournalArchives of Ophthalmology
Volume107
Issue number9
DOIs
StatePublished - 1989

Fingerprint

Iontophoresis
Cryotherapy
Dexamethasone
Vitreous Body
dexamethasone 21-phosphate
Retina
Pharmaceutical Preparations
Ticarcillin
Rabbits
Cefazolin
Gentamicins
Edetic Acid
Half-Life
Adrenal Cortex Hormones
Nitrogen
High Pressure Liquid Chromatography

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Transscleral Iontophoresis of Dexamethasone. / Lam, Tim T.; Edward, Deepak P.; Zhu, Xiu An; Tso, Mark O M.

In: Archives of Ophthalmology, Vol. 107, No. 9, 1989, p. 1368-1371.

Research output: Contribution to journalArticle

Lam, Tim T. ; Edward, Deepak P. ; Zhu, Xiu An ; Tso, Mark O M. / Transscleral Iontophoresis of Dexamethasone. In: Archives of Ophthalmology. 1989 ; Vol. 107, No. 9. pp. 1368-1371.
@article{c521d014e7ed4b8dbdac6faeff8a299d,
title = "Transscleral Iontophoresis of Dexamethasone",
abstract = "Transscleral iontophoresis has been suggested to be a potentially useful noninvasive technique in intravitreal introduction of ionizable drugs, such as cefazolin sodium, ticarcillin disodium, and gentamicin sulfate. To investigate the usefulness of this technique in the administration of corticosteroids, we performed transscleral iontophoresis of dexamethasone sodium phosphate (300 mg/mL, 20 mmol/L edetic acid [EDTA]) into rabbits at a current of 1.6 mA for 25 minutes. Eyes were enucleated at different time intervals and frozen in liquid nitrogen. The frozen vitreous bodies and adherent sensory retina were collected and sonicated, and dexamethasone levels were measured using high-pressure liquid chromatography. In addition, to study the facilitation of drug transport by cryotherapy, a second group of rabbits were given a single application of cryotherapy (—78°C, 45 seconds) 3, 7, and 14 days before iontophoresis in the same region. Without cryotherapy, the initial level of dexamethasone in the vitreous body—sensory retina after iontophoresis was 139.3 ± 51.5 mg/L (mean ± SE) (n = 6) with a half-life of less than 2 hours. In the cryotreated group, the levels of dexamethasone immediately after iontophoresis 3, 7, and 14 days after cryotherapy were 61.5 ± 31.7 (n = 6), 88.4 ± 55.1 (n = 6), and 112.2 ± 32.5 (n = 6) mg/L, respectively, indicating that levels were lower compared with the group without cryotherapy. Our results suggest that a high dose of dexamethasone can be delivered by using this noninvasive technique and that cryotherapy before iontophoresis does not increase drug levels in the vitreous body.",
author = "Lam, {Tim T.} and Edward, {Deepak P.} and Zhu, {Xiu An} and Tso, {Mark O M}",
year = "1989",
doi = "10.1001/archopht.1989.01070020438050",
language = "English (US)",
volume = "107",
pages = "1368--1371",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Transscleral Iontophoresis of Dexamethasone

AU - Lam, Tim T.

AU - Edward, Deepak P.

AU - Zhu, Xiu An

AU - Tso, Mark O M

PY - 1989

Y1 - 1989

N2 - Transscleral iontophoresis has been suggested to be a potentially useful noninvasive technique in intravitreal introduction of ionizable drugs, such as cefazolin sodium, ticarcillin disodium, and gentamicin sulfate. To investigate the usefulness of this technique in the administration of corticosteroids, we performed transscleral iontophoresis of dexamethasone sodium phosphate (300 mg/mL, 20 mmol/L edetic acid [EDTA]) into rabbits at a current of 1.6 mA for 25 minutes. Eyes were enucleated at different time intervals and frozen in liquid nitrogen. The frozen vitreous bodies and adherent sensory retina were collected and sonicated, and dexamethasone levels were measured using high-pressure liquid chromatography. In addition, to study the facilitation of drug transport by cryotherapy, a second group of rabbits were given a single application of cryotherapy (—78°C, 45 seconds) 3, 7, and 14 days before iontophoresis in the same region. Without cryotherapy, the initial level of dexamethasone in the vitreous body—sensory retina after iontophoresis was 139.3 ± 51.5 mg/L (mean ± SE) (n = 6) with a half-life of less than 2 hours. In the cryotreated group, the levels of dexamethasone immediately after iontophoresis 3, 7, and 14 days after cryotherapy were 61.5 ± 31.7 (n = 6), 88.4 ± 55.1 (n = 6), and 112.2 ± 32.5 (n = 6) mg/L, respectively, indicating that levels were lower compared with the group without cryotherapy. Our results suggest that a high dose of dexamethasone can be delivered by using this noninvasive technique and that cryotherapy before iontophoresis does not increase drug levels in the vitreous body.

AB - Transscleral iontophoresis has been suggested to be a potentially useful noninvasive technique in intravitreal introduction of ionizable drugs, such as cefazolin sodium, ticarcillin disodium, and gentamicin sulfate. To investigate the usefulness of this technique in the administration of corticosteroids, we performed transscleral iontophoresis of dexamethasone sodium phosphate (300 mg/mL, 20 mmol/L edetic acid [EDTA]) into rabbits at a current of 1.6 mA for 25 minutes. Eyes were enucleated at different time intervals and frozen in liquid nitrogen. The frozen vitreous bodies and adherent sensory retina were collected and sonicated, and dexamethasone levels were measured using high-pressure liquid chromatography. In addition, to study the facilitation of drug transport by cryotherapy, a second group of rabbits were given a single application of cryotherapy (—78°C, 45 seconds) 3, 7, and 14 days before iontophoresis in the same region. Without cryotherapy, the initial level of dexamethasone in the vitreous body—sensory retina after iontophoresis was 139.3 ± 51.5 mg/L (mean ± SE) (n = 6) with a half-life of less than 2 hours. In the cryotreated group, the levels of dexamethasone immediately after iontophoresis 3, 7, and 14 days after cryotherapy were 61.5 ± 31.7 (n = 6), 88.4 ± 55.1 (n = 6), and 112.2 ± 32.5 (n = 6) mg/L, respectively, indicating that levels were lower compared with the group without cryotherapy. Our results suggest that a high dose of dexamethasone can be delivered by using this noninvasive technique and that cryotherapy before iontophoresis does not increase drug levels in the vitreous body.

UR - http://www.scopus.com/inward/record.url?scp=0024421694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024421694&partnerID=8YFLogxK

U2 - 10.1001/archopht.1989.01070020438050

DO - 10.1001/archopht.1989.01070020438050

M3 - Article

VL - 107

SP - 1368

EP - 1371

JO - JAMA Ophthalmology

JF - JAMA Ophthalmology

SN - 2168-6165

IS - 9

ER -